The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma

Laryngoscope

Volumn 112, Issue 12, 2002, Pages 2114-2128

  Yarbrough, Wendell G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Alternate reading frame of p16 gene; Familial tumor syndrome; Head and neck squamous cell carcinoma; p16

Indexed keywords

ARF PROTEIN; GENE PRODUCT; MUTANT PROTEIN; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ALLELE; ARTICLE; CANCER FAMILY; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENE SEGREGATION; GENETIC PREDISPOSITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0036896045     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200212000-00002     Document Type: Article

References (84)

1. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.
2. Hahn WC, et al. Creation of human tumor cells with defined genetic elements. Nature 1999;400:464-468.
3. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
4. Sherr CJ. Cancer cell cycle. Science 1996;274:1672-1677.
5. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
6. Gottlieb MT, Oren M. p53 in growth control and neoplasia. Biochem Biophys Acta 1996;1287:77-102.
7. Ko LJ, Prives C. p53 puzzle and paradigm. Genes Dev 1996; 10:1054-1072.
8. Jacks T, et al. Effects of an Rb mutation in the mouse. Nature 1992;359:295-300.
9. Lee EY-HP, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992;359:294.
10. Donehower LA, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
11. Whyte P, et al. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988;334:124-129.
12. Dyson N, et al. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 1989;58:249-255.
13. DeCaprio JA, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;54:275-283.
14. Hinds PW, et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992;70: 993-1006.
15. Dowdy SF, et al. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511.
16. Ewen ME, et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73:487-497.
17. Kato J, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7:331-342.
18. Scheffner M, et al. The HPV-16 E6 and E6AP complex function as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505.
19. Haupt Y, et al. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
20. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
21. Oliner JD, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358: 80-83.
22. Oliner JD, et al. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993;362: 857-860.
23. Momand J, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
24. Leach FS, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53: 2231-2234.
25. Luna RM, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-206.
26. Jones SN, et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378: 206-208.
27. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
28. Hainaut P, et al. IARC Database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998;26:205-213.
29. Reed AL, et al. High frequency of p16 (CDKN2/MTS-1 INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3633.
30. Shahnavaz SA, et al. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. Cancer Res 2001;61:2371-2375.
31. Quelle DE, et al. Alternative reading frames of the INK4a tumors suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
32. ARF. Cell 1997;91:649-659.
33. Stone S, et al. Complex structure and regulation of the P16 locus. Cancer Res 1995;55:2988-2933.
34. Mao L, et al. A novel p16/INK4a transcript. Cancer Res 1995; 55:2995-2997.
35. Duro D, et al. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995;11:21-29.
36. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993;7:1572-1583.
37. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
38. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-734.
39. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22-27.
40. Tao W, Levine AJ. P19ARF stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A 1999;96:6937-6941.
41. Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999;3:1-20.
42. Serrano M, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
43. Kamb A, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-26.
44. Gruis NA, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995; 146:1199-1206.
45. Ruas M, Peters G. The p16INK4a/CDK2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;14: F115-F177.
46. INK4 mutations. N Engl J Med 1995;333:970-974.
47. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-977.
48. Reymond A, Brent R. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 1995; 11:1173-1178.
49. Koh J, et al. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375: 506-510.
50. INK4 function. Nat Genet 1995;10: 114-116.
51. Yarbrough WG, et al. Biologic and biochemical analyses of p16INK4a mutations from primary tumors. J Natl Cancer Inst 1999;91:1569-1574.
52. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000;19:2312-2323.
53. Krimpenfort P, Quon KC, Mooi WJL. A loss of p16INK4a confers susceptibility to metastatic melanoma in mice. Nature 2001;413:83-86.
54. Larsen, C-J. p16INK4a: A gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene 1996;12:2041-2044.
55. Gardie B, et al. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91:1016-1020.
56. Robertson KD, Jones PA. The human arf cell cycle regulatory gene promoter is a cpg island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 1998;18:6457-6471.
57. ARF predisposes mice to tumorigenesis. Nature 2001;413: 86-91.
58. Mobley SR, et al. In vitro growth suppress by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: A research model for combination gene therapy. Arch Otolaryngol Head Neck Surg 1998;124: 88-92.
59. Fueyo J, et al. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy. Int J Oncol 1998;12: 665-669.
60. ARF tumor suppressor. Genes Dev 1998;12:2434-2442.
61. Radfar A, et al. p19ARF induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A 1998;95:13194-13199.
62. Eischen CM, et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13:2658-2669.
63. Heise C, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-645.
64. Ankathil R, et al. Is oral cancer susceptibility inherited? Report of five oral cancer families. Oral Oncol Eur J Cancer 1996;32B:63-67.
65. Copper MP, et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995;121:157-160.
66. Olshan AF, et al. Alterations of the p16 gene in head and neck cancer: Frequency and association with p53, PRAD-1 and HPV. Oncogene 1997;14:811-818.
67. INK4a allele. J Natl Cancer Inst 1996;88:1489-1491.
68. Hussussian CJ, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
69. Hutchin ME, Pickles RJ, Yarbrough WG. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum Gene Ther 2000;11:2365-2375.
70. Tam SW, et al. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: Association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene 1994;9:2663-2674.
71. Liggett WH, et al. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cell in vitro. Cancer Res 1996;56:4119-4123.
72. Silverman D, et al. Alcohol and pancreatic cancer in blacks and whites in the United States. Cancer Res 1995;51: 4899-4905.
73. Zheng W, et al. A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control 1993;4:477-482.
74. Otterson GA, et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-3378.
75. Zhou X, et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994;9: 3737-3741.
76. Mori T, et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-3397.
77. Washimi O, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995;55:514-517.
78. Reed JA, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-2718.
79. Gombart AF, et al. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4a and p15INK4b in non-Hodgkin's lymphoma. Blood 1995;86:1534-1539.
80. Kyritsis AP, et al. Mutations of the p16 gene in gliomas. Oncogene 1996;12:63-67.
81. Cairns P, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11: 210-212.
82. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
83. Nemunaitis J, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head neck cancer: A Phase II trial. Cancer Res 2000;60:6359-6366.
84. Byron I-JL, et al. Tumor suppressor p16INK4A: Determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell 1998;1:421-431.